 Jessica Kendrick
Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 13 | 2018 | 486 | 2.730 |
Why?
| | Renal Dialysis | 8 | 2021 | 369 | 2.640 |
Why?
| | Kidney Failure, Chronic | 10 | 2018 | 487 | 2.340 |
Why?
| | Phosphorus | 5 | 2019 | 81 | 2.010 |
Why?
| | Hyperparathyroidism, Secondary | 3 | 2021 | 9 | 1.490 |
Why?
| | Kidney Diseases | 7 | 2022 | 350 | 1.370 |
Why?
| | Acidosis | 2 | 2021 | 87 | 1.300 |
Why?
| | Cardiovascular Diseases | 11 | 2018 | 1727 | 1.280 |
Why?
| | Bicarbonates | 2 | 2020 | 41 | 1.260 |
Why?
| | Pregnancy Complications | 3 | 2018 | 429 | 1.230 |
Why?
| | Glomerular Filtration Rate | 9 | 2024 | 604 | 1.140 |
Why?
| | Vitamin D | 10 | 2018 | 341 | 1.130 |
Why?
| | Acute Kidney Injury | 3 | 2023 | 637 | 1.100 |
Why?
| | Blood Pressure | 5 | 2016 | 1530 | 1.070 |
Why?
| | Kidney | 10 | 2024 | 1184 | 0.990 |
Why?
| | Potassium | 2 | 2014 | 128 | 0.910 |
Why?
| | Glomerulonephritis, IGA | 1 | 2023 | 7 | 0.880 |
Why?
| | Vitamin D Deficiency | 5 | 2013 | 158 | 0.820 |
Why?
| | Hypertension | 4 | 2016 | 1059 | 0.810 |
Why?
| | Kidney Transplantation | 2 | 2018 | 541 | 0.810 |
Why?
| | Transition to Adult Care | 1 | 2023 | 63 | 0.800 |
Why?
| | Complement Factor B | 1 | 2023 | 100 | 0.800 |
Why?
| | Calcimimetic Agents | 1 | 2021 | 2 | 0.790 |
Why?
| | Healthcare Disparities | 2 | 2017 | 479 | 0.740 |
Why?
| | Infant Mortality | 2 | 2018 | 91 | 0.730 |
Why?
| | Infant, Low Birth Weight | 2 | 2018 | 125 | 0.720 |
Why?
| | Pregnancy Outcome | 3 | 2018 | 337 | 0.670 |
Why?
| | Pre-Eclampsia | 2 | 2018 | 165 | 0.650 |
Why?
| | Nutrition Surveys | 5 | 2014 | 224 | 0.650 |
Why?
| | Hyperphosphatemia | 1 | 2019 | 13 | 0.650 |
Why?
| | Ferric Compounds | 1 | 2019 | 40 | 0.630 |
Why?
| | Sucrose | 1 | 2019 | 91 | 0.630 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 40 | 0.620 |
Why?
| | Bone Diseases, Metabolic | 1 | 2018 | 53 | 0.590 |
Why?
| | Calcium | 3 | 2021 | 1103 | 0.590 |
Why?
| | Antihypertensive Agents | 3 | 2016 | 429 | 0.580 |
Why?
| | Renal Insufficiency | 1 | 2019 | 136 | 0.560 |
Why?
| | Living Donors | 1 | 2018 | 270 | 0.540 |
Why?
| | Minerals | 2 | 2015 | 37 | 0.540 |
Why?
| | Nutritional Status | 2 | 2019 | 286 | 0.530 |
Why?
| | Humans | 48 | 2024 | 114714 | 0.520 |
Why?
| | Risk Factors | 12 | 2020 | 8626 | 0.500 |
Why?
| | Phosphates | 2 | 2019 | 158 | 0.500 |
Why?
| | Fibroblast Growth Factors | 4 | 2012 | 162 | 0.480 |
Why?
| | Vascular Calcification | 2 | 2018 | 107 | 0.480 |
Why?
| | Diabetic Nephropathies | 3 | 2022 | 234 | 0.480 |
Why?
| | Endothelium, Vascular | 2 | 2018 | 843 | 0.480 |
Why?
| | Parathyroid Hormone | 5 | 2021 | 95 | 0.460 |
Why?
| | Aged | 19 | 2020 | 19079 | 0.460 |
Why?
| | Sodium Chloride, Dietary | 1 | 2014 | 30 | 0.460 |
Why?
| | Middle Aged | 22 | 2019 | 26746 | 0.450 |
Why?
| | Sodium | 1 | 2014 | 182 | 0.450 |
Why?
| | Male | 29 | 2024 | 55558 | 0.450 |
Why?
| | Atherosclerosis | 2 | 2016 | 342 | 0.450 |
Why?
| | Female | 30 | 2024 | 59485 | 0.450 |
Why?
| | Potassium, Dietary | 1 | 2013 | 10 | 0.440 |
Why?
| | Heart Arrest | 1 | 2016 | 289 | 0.430 |
Why?
| | Sodium, Dietary | 1 | 2013 | 36 | 0.430 |
Why?
| | Kidney Function Tests | 2 | 2010 | 140 | 0.410 |
Why?
| | Perception | 1 | 2015 | 311 | 0.410 |
Why?
| | Myocardial Infarction | 2 | 2016 | 927 | 0.390 |
Why?
| | Health Services Accessibility | 1 | 2017 | 763 | 0.390 |
Why?
| | Disease Management | 1 | 2015 | 560 | 0.380 |
Why?
| | Clinical Trials as Topic | 2 | 2022 | 934 | 0.380 |
Why?
| | Adult | 16 | 2024 | 30543 | 0.380 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 1078 | 0.370 |
Why?
| | Diet | 2 | 2017 | 1080 | 0.360 |
Why?
| | Follow-Up Studies | 6 | 2018 | 4420 | 0.360 |
Why?
| | Patient Selection | 1 | 2014 | 641 | 0.360 |
Why?
| | Ankle Brachial Index | 1 | 2010 | 30 | 0.360 |
Why?
| | Stroke | 2 | 2016 | 1019 | 0.350 |
Why?
| | Lovastatin | 1 | 2009 | 26 | 0.340 |
Why?
| | Patient Education as Topic | 1 | 2014 | 679 | 0.340 |
Why?
| | Health Status | 1 | 2014 | 723 | 0.320 |
Why?
| | Prospective Studies | 6 | 2023 | 6216 | 0.320 |
Why?
| | United States | 9 | 2018 | 12176 | 0.320 |
Why?
| | Cohort Studies | 6 | 2019 | 4899 | 0.320 |
Why?
| | Renal Artery Obstruction | 1 | 2008 | 29 | 0.310 |
Why?
| | Primary Prevention | 1 | 2009 | 172 | 0.300 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 977 | 0.300 |
Why?
| | Proportional Hazards Models | 3 | 2016 | 1080 | 0.290 |
Why?
| | Colitis, Ischemic | 1 | 2007 | 6 | 0.290 |
Why?
| | Incidence | 4 | 2018 | 2312 | 0.290 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2007 | 25 | 0.290 |
Why?
| | Escherichia coli O157 | 1 | 2007 | 30 | 0.290 |
Why?
| | Critical Illness | 2 | 2023 | 643 | 0.280 |
Why?
| | Hemoglobins | 1 | 2009 | 314 | 0.280 |
Why?
| | Health Surveys | 1 | 2008 | 443 | 0.280 |
Why?
| | Escherichia coli Infections | 1 | 2007 | 100 | 0.270 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1183 | 0.270 |
Why?
| | Insulin Resistance | 3 | 2024 | 1072 | 0.260 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2024 | 2096 | 0.250 |
Why?
| | Primary Health Care | 1 | 2015 | 1515 | 0.240 |
Why?
| | Treatment Outcome | 7 | 2019 | 9089 | 0.230 |
Why?
| | Heart Failure | 1 | 2016 | 1952 | 0.230 |
Why?
| | Coronary Artery Disease | 1 | 2009 | 607 | 0.220 |
Why?
| | Albuminuria | 3 | 2020 | 164 | 0.220 |
Why?
| | Proteinuria | 1 | 2023 | 77 | 0.210 |
Why?
| | Hyperoxia | 1 | 2024 | 100 | 0.210 |
Why?
| | Kidney Glomerulus | 1 | 2023 | 100 | 0.210 |
Why?
| | Military Personnel | 1 | 2009 | 523 | 0.200 |
Why?
| | Infant, Newborn | 3 | 2018 | 5034 | 0.200 |
Why?
| | Disease Progression | 4 | 2015 | 2384 | 0.200 |
Why?
| | Prevalence | 4 | 2017 | 2249 | 0.200 |
Why?
| | Inflammation | 2 | 2009 | 2481 | 0.190 |
Why?
| | Pregnancy | 3 | 2018 | 5524 | 0.190 |
Why?
| | Double-Blind Method | 4 | 2015 | 1662 | 0.180 |
Why?
| | Fruit | 1 | 2021 | 128 | 0.180 |
Why?
| | Young Adult | 4 | 2024 | 10462 | 0.180 |
Why?
| | Time Factors | 3 | 2019 | 6124 | 0.180 |
Why?
| | Calcinosis | 2 | 2014 | 242 | 0.180 |
Why?
| | Aged, 80 and over | 5 | 2017 | 6346 | 0.170 |
Why?
| | Complement System Proteins | 1 | 2022 | 285 | 0.170 |
Why?
| | Biomarkers | 3 | 2023 | 3414 | 0.160 |
Why?
| | Creatinine | 2 | 2020 | 424 | 0.160 |
Why?
| | Chelating Agents | 1 | 2019 | 65 | 0.160 |
Why?
| | Receptors, Calcium-Sensing | 1 | 2018 | 5 | 0.160 |
Why?
| | Vitamin D-Binding Protein | 1 | 2018 | 13 | 0.160 |
Why?
| | Retrospective Studies | 5 | 2021 | 12512 | 0.160 |
Why?
| | Intestinal Absorption | 1 | 2018 | 93 | 0.150 |
Why?
| | Drug Combinations | 1 | 2019 | 286 | 0.150 |
Why?
| | Case-Control Studies | 4 | 2018 | 3004 | 0.150 |
Why?
| | Comorbidity | 2 | 2015 | 1449 | 0.140 |
Why?
| | Metformin | 1 | 2020 | 277 | 0.140 |
Why?
| | Cross-Over Studies | 1 | 2018 | 440 | 0.140 |
Why?
| | Prognosis | 2 | 2018 | 3334 | 0.140 |
Why?
| | Adolescent | 5 | 2024 | 17808 | 0.140 |
Why?
| | Diuretics | 1 | 2016 | 66 | 0.140 |
Why?
| | Peptides | 1 | 2021 | 848 | 0.140 |
Why?
| | Congenital Abnormalities | 1 | 2017 | 73 | 0.140 |
Why?
| | Odds Ratio | 3 | 2014 | 954 | 0.130 |
Why?
| | Waiting Lists | 1 | 2017 | 211 | 0.130 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2015 | 76 | 0.120 |
Why?
| | Polymorphism, Genetic | 1 | 2018 | 612 | 0.120 |
Why?
| | Maternal Mortality | 1 | 2015 | 30 | 0.120 |
Why?
| | Obstetric Labor, Premature | 1 | 2015 | 33 | 0.120 |
Why?
| | Precision Medicine | 1 | 2018 | 338 | 0.120 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 179 | 0.120 |
Why?
| | Transcription Factor CHOP | 1 | 2014 | 28 | 0.120 |
Why?
| | Risk Assessment | 2 | 2017 | 2973 | 0.120 |
Why?
| | Cultural Competency | 1 | 2015 | 72 | 0.120 |
Why?
| | Infant, Small for Gestational Age | 1 | 2015 | 76 | 0.120 |
Why?
| | Ethics Committees, Research | 1 | 2014 | 38 | 0.120 |
Why?
| | Medication Adherence | 1 | 2019 | 537 | 0.110 |
Why?
| | Awareness | 1 | 2015 | 93 | 0.110 |
Why?
| | Infant | 2 | 2018 | 7934 | 0.110 |
Why?
| | Pilot Projects | 1 | 2018 | 1370 | 0.110 |
Why?
| | Premature Birth | 1 | 2017 | 276 | 0.110 |
Why?
| | Professional-Patient Relations | 1 | 2015 | 141 | 0.110 |
Why?
| | Cesarean Section | 1 | 2015 | 169 | 0.110 |
Why?
| | Pneumonia, Bacterial | 1 | 2014 | 106 | 0.110 |
Why?
| | Global Health | 1 | 2015 | 288 | 0.110 |
Why?
| | Simvastatin | 2 | 2014 | 59 | 0.110 |
Why?
| | Cause of Death | 1 | 2015 | 362 | 0.110 |
Why?
| | Health Care Surveys | 1 | 2015 | 539 | 0.110 |
Why?
| | Community-Acquired Infections | 1 | 2014 | 141 | 0.100 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 176 | 0.100 |
Why?
| | Cross-Sectional Studies | 3 | 2013 | 4406 | 0.100 |
Why?
| | Logistic Models | 3 | 2014 | 1843 | 0.100 |
Why?
| | Academic Medical Centers | 1 | 2015 | 413 | 0.100 |
Why?
| | Endoplasmic Reticulum | 1 | 2014 | 234 | 0.100 |
Why?
| | Cooperative Behavior | 1 | 2014 | 381 | 0.100 |
Why?
| | Chronic Disease | 4 | 2012 | 1590 | 0.100 |
Why?
| | Vascular Diseases | 1 | 2014 | 230 | 0.100 |
Why?
| | Survival Rate | 1 | 2015 | 1642 | 0.090 |
Why?
| | Infant, Premature | 1 | 2015 | 478 | 0.090 |
Why?
| | Research | 1 | 2014 | 393 | 0.090 |
Why?
| | Metabolic Diseases | 1 | 2012 | 99 | 0.090 |
Why?
| | Fatty Liver | 1 | 2013 | 213 | 0.090 |
Why?
| | Length of Stay | 1 | 2015 | 949 | 0.090 |
Why?
| | Tunica Media | 1 | 2010 | 35 | 0.090 |
Why?
| | Tunica Intima | 1 | 2010 | 78 | 0.080 |
Why?
| | Child | 3 | 2023 | 18350 | 0.080 |
Why?
| | Systole | 1 | 2010 | 171 | 0.080 |
Why?
| | Complement Activation | 2 | 2022 | 340 | 0.080 |
Why?
| | Metabolic Syndrome | 1 | 2012 | 323 | 0.080 |
Why?
| | Communication | 1 | 2015 | 747 | 0.080 |
Why?
| | Texas | 1 | 2009 | 188 | 0.080 |
Why?
| | Bone and Bones | 1 | 2012 | 278 | 0.080 |
Why?
| | Radioisotope Renography | 1 | 2008 | 4 | 0.080 |
Why?
| | Tomography, Spiral Computed | 1 | 2008 | 23 | 0.080 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2008 | 33 | 0.080 |
Why?
| | Calcium, Dietary | 1 | 2009 | 55 | 0.080 |
Why?
| | Cholecalciferol | 1 | 2009 | 47 | 0.080 |
Why?
| | Sepsis | 1 | 2014 | 508 | 0.080 |
Why?
| | Cardiovascular System | 1 | 2010 | 125 | 0.080 |
Why?
| | Causality | 1 | 2008 | 104 | 0.080 |
Why?
| | Age Distribution | 1 | 2008 | 339 | 0.070 |
Why?
| | Vitamins | 1 | 2009 | 151 | 0.070 |
Why?
| | Sex Distribution | 1 | 2008 | 335 | 0.070 |
Why?
| | Homeostasis | 1 | 2011 | 575 | 0.070 |
Why?
| | Anemia | 1 | 2008 | 144 | 0.070 |
Why?
| | Oxidative Stress | 2 | 2014 | 1084 | 0.070 |
Why?
| | Anastomosis, Surgical | 1 | 2007 | 136 | 0.070 |
Why?
| | Biopsy, Needle | 1 | 2007 | 181 | 0.070 |
Why?
| | C-Reactive Protein | 1 | 2009 | 362 | 0.070 |
Why?
| | Colectomy | 1 | 2007 | 86 | 0.070 |
Why?
| | Magnetic Resonance Angiography | 1 | 2008 | 219 | 0.070 |
Why?
| | Rare Diseases | 1 | 2007 | 89 | 0.070 |
Why?
| | Coronary Disease | 1 | 2008 | 347 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1214 | 0.070 |
Why?
| | Abdominal Pain | 1 | 2007 | 135 | 0.070 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 372 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 1846 | 0.060 |
Why?
| | Ischemia | 1 | 2008 | 362 | 0.060 |
Why?
| | Survival Analysis | 1 | 2008 | 1218 | 0.060 |
Why?
| | Colorado | 1 | 2015 | 4086 | 0.060 |
Why?
| | Dietary Supplements | 1 | 2009 | 460 | 0.060 |
Why?
| | Colonoscopy | 1 | 2007 | 205 | 0.060 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2382 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2020 | 3248 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 4622 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2009 | 2538 | 0.050 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1635 | 0.050 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 1 | 2022 | 18 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 530 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2015 | 954 | 0.050 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 71 | 0.050 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2022 | 100 | 0.050 |
Why?
| | Oxygen | 1 | 2024 | 853 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2021 | 618 | 0.040 |
Why?
| | Phenotype | 1 | 2022 | 2811 | 0.030 |
Why?
| | Ketocholesterols | 1 | 2014 | 8 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2022 | 1008 | 0.030 |
Why?
| | Ezetimibe | 1 | 2014 | 24 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 56 | 0.030 |
Why?
| | Azetidines | 1 | 2014 | 31 | 0.030 |
Why?
| | Insulin | 1 | 2024 | 2079 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2014 | 80 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2014 | 89 | 0.030 |
Why?
| | Pulse Wave Analysis | 1 | 2014 | 207 | 0.030 |
Why?
| | Brachial Artery | 1 | 2014 | 176 | 0.030 |
Why?
| | Aorta | 1 | 2014 | 386 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 494 | 0.020 |
Why?
| | Lipids | 1 | 2014 | 582 | 0.020 |
Why?
| | Risk | 1 | 2012 | 815 | 0.020 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2013 | 245 | 0.020 |
Why?
| | Linear Models | 1 | 2012 | 770 | 0.020 |
Why?
| | Ultrasonography | 1 | 2013 | 629 | 0.020 |
Why?
| | Scandinavian and Nordic Countries | 1 | 2008 | 6 | 0.020 |
Why?
| | Placebos | 1 | 2008 | 198 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1435 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 2582 | 0.020 |
Why?
| | Body Mass Index | 1 | 2013 | 1958 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2011 | 723 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 4710 | 0.020 |
Why?
| | Animals | 1 | 2014 | 31761 | 0.010 |
Why?
|
|
Kendrick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|